Technical Analysis for JAZZ - Jazz Pharmaceuticals plc

Grade Last Price % Change Price Change
B 164.75 2.68% 4.30
JAZZ closed up 2.68 percent on Friday, March 5, 2021, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical JAZZ trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
Outside Day Range Expansion 0.00%
20 DMA Resistance Bearish 2.68%
Fell Below 50 DMA Bearish 2.68%
MACD Bearish Signal Line Cross Bearish 2.68%
Spinning Top Other 2.68%
Calm After Storm Range Contraction 2.68%
Older End-of-Day Signals for JAZZ ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Jazz Pharmaceuticals plc Description

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma; Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Pain Drugs Pharmaceutical Products Bone Imaging Monoclonal Antibody Lymphoma Prostate Cancer Antibiotic Symptoms Schizophrenia Chronic Pain Suspension Transplantation Acute Lymphoblastic Leukemia Movement Disorders Pharmacokinetics Bones Host Disease Narcolepsy Obsessive Compulsive Disorder Meningitis Oral Hygiene Organ Transplantation Pegylation Severe Chronic Pain Cataplexy Host Diseases Mucositis Organ Transplant Asparaginase Luvox Cr Oral Mucositis Panic Disorder

Is JAZZ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 178.64
52 Week Low 86.9539
Average Volume 742,999
200-Day Moving Average 138.84
50-Day Moving Average 162.81
20-Day Moving Average 164.71
10-Day Moving Average 165.41
Average True Range 6.25
ADX 17.26
+DI 23.21
-DI 21.14
Chandelier Exit (Long, 3 ATRs ) 159.90
Chandelier Exit (Short, 3 ATRs ) 164.75
Upper Bollinger Band 173.22
Lower Bollinger Band 156.21
Percent B (%b) 0.5
BandWidth 10.32
MACD Line 0.90
MACD Signal Line 1.25
MACD Histogram -0.3482
Fundamentals Value
Market Cap 9.18 Billion
Num Shares 55.7 Million
EPS 3.16
Price-to-Earnings (P/E) Ratio 52.10
Price-to-Sales 3.55
Price-to-Book 2.36
PEG Ratio 4.98
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 176.80
Resistance 3 (R3) 175.91 171.00 174.79
Resistance 2 (R2) 171.00 167.94 171.45 174.12
Resistance 1 (R1) 167.88 166.04 169.44 168.77 173.45
Pivot Point 162.97 162.97 163.76 163.42 162.97
Support 1 (S1) 159.85 159.91 161.41 160.74 156.05
Support 2 (S2) 154.94 158.01 155.39 155.38
Support 3 (S3) 151.82 154.94 154.71
Support 4 (S4) 152.71